UK HealthCare

Markey study: Molecular tumor boards improve outcomes for patients with advanced cancer

The Molecular Tumor Board is codirected by Rachel Miller, M.D., and Jill Kolesar, Pharm.D. (photo taken in 2017) Mark Cornelison | UK Photo
The Molecular Tumor Board is co-directed by Rachel Miller, M.D., and Jill Kolesar, Pharm.D. (photo taken in 2017). Mark Cornelison | UK Photo.

LEXINGTON, Ky. (Sept. 22, 2022) — In a recent University of Kentucky Markey Cancer Center clinical trial, patients with advanced cancer experienced improved outcomes when their treatments were directed by a molecular tumor board.

Molecular tumor boards (MTB) are composed of an interdisciplinary team of medical experts who use tumor genomic analysis to help oncologists choose cancer therapies tailored to each patient’s individual needs. When a physician requests a MTB review, patients' tumors are tested for mutations using next-generation sequencing. The board then evaluates the report and may recommend three types of potential care: therapies for that patient's cancer type that are approved by the Food and Drug Administration (FDA), FDA-approved therapies in another tumor type and potential clinical trials.

Results published in JCO Precision Oncology Sept. 14 demonstrate that the MTB review process improves overall survival rates for patients with advanced cancer.

Patients participating in the phase II clinical trial received therapy directed by UK Markey Cancer Center’s MTB between 2017 and 2020.

The study provides important data that supports the clinical use of MTBs in cancer care, says study author Jill Kolesar, Pharm.D., a professor in UK’s College of Pharmacy who directs Markey’s Precision Medicine Center and co-directs the MTB.

“As personalized cancer therapies are quickly becoming approved for multiple molecular targets, MTBs may help oncologists choose the most effective therapy option,” said Kolesar. “The study suggests that the precision medicine expertise offered by a MTB can lead to better outcomes even for patients with advanced cancer who have already received treatment.”

All 93 enrolled patients had advanced cancer with tumors that had actionable mutations, or DNA mutations that can be targeted with an available treatment.

The study measured their progression-free survival, or the length of time during and after a treatment that a patient lives with cancer, but it does not get worse. By comparing the MTB-directed therapy with the patients’ immediately prior therapy, the study allowed patients to serve as their own control.

“When treated with MTB-directed therapy, most patients experienced improved progression-free survival compared with immediately prior treatment. MTB-directed targeted therapy may be a strategy to improve outcomes for patients with advanced cancer,” the study concludes.

Launched in 2016, the UK Markey Cancer Center MTB includes representation from medical oncology, surgical oncology, pathology, radiology, genetic counseling and clinical pharmacology.

By analyzing the molecular characteristics of cancer tumors on a case-by-case basis, the MTB also creates a cache of information to direct the development of new therapies and clinical trials that target the types of cancers found at Markey and throughout Kentucky.

Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number P30CA177558. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

The University of Kentucky is increasingly the first choice for students, faculty and staff to pursue their passions and their professional goals. In the last two years, Forbes has named UK among the best employers for diversity, and INSIGHT into Diversity recognized us as a Diversity Champion four years running. UK is ranked among the top 30 campuses in the nation for LGBTQ* inclusion and safety. UK has been judged a “Great College to Work for" three years in a row, and UK is among only 22 universities in the country on Forbes' list of "America's Best Employers."  We are ranked among the top 10 percent of public institutions for research expenditures — a tangible symbol of our breadth and depth as a university focused on discovery that changes lives and communities. And our patients know and appreciate the fact that UK HealthCare has been named the state’s top hospital for five straight years. Accolades and honors are great. But they are more important for what they represent: the idea that creating a community of belonging and commitment to excellence is how we honor our mission to be not simply the University of Kentucky, but the University for Kentucky.